telcagepant
Small moleculeexperimental
Telcagepant is a calcitonin gene-related peptide receptor antagonist which was an investigational drug for the acute treatment and prevention of migraine, developed by Merck & Co. — Wikipedia
Clinical trial activity
14 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
8
Phase 3
6
Phase 4
0
Earliest trial started Nov 1, 2005 (NCT00246337)
Timeline
Indications
Mechanism of action
CALCRL antagonist
Chemistry & pharmacology
Loading structure…
SMILES
O=C(N[C@@H]1CC[C@@H](c2cccc(F)c2F)CN(CC(F)(F)F)C1=O)N1CCC(n2c(=O)[nH]c3ncccc32)CC1- Mol. weight
- 566.53 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaTelcagepant ↗
- ChEMBLCHEMBL236593 ↗
Also known as
- mk0974
- mk0974
- mk0974
- mk 0974
- mk-0974
- mk-0974
- mk-0974
- mk-0974
- n-((3r,6s)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)hexahydro-1h-azepin-3- yl)-4-(2-oxo-2,3-dihydro-1h-imidazo(4,5-b)pyridin-1-yl)piperidine-1-carboxamide
- n-(6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl)-4-(2-oxo-2,3-dihydro-1h-imidazo(4,5-b)pyridin-1-yl)piperidine-1-carboxamide
- talcagepant
- tecagepant
- telcagepant
- telcagepant
- telcagepant
- telcagepant
- telcagepant
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01125774 | Phase 2/Phase 3 (Phase 3) | Jun 1, 2010 | Merck |
| NCT01315847 | Phase 1 | Jan 1, 2010 | Merck |
| NCT00758836 | Phase 2 | Dec 1, 2008 | Merck |
| NCT00797667 | Phase 2 | Nov 1, 2008 | Merck |
| NCT00483704 | Phase 3 | Aug 14, 2008 | Merck |
| NCT00662818 | Phase 3 | Mar 17, 2008 | Merck |
| NCT00966030 | Phase 1 | Mar 1, 2008 | Merck |
| NCT00965887 | Phase 1 | Mar 1, 2008 | Merck |
| NCT01294709 | Phase 1 | Feb 12, 2008 | Merck |
| NCT01209741 | Phase 1 | Oct 1, 2007 | Merck |
| NCT00432237 | Phase 3 | Mar 1, 2007 | Merck |
| NCT00443209 | Phase 3 | Feb 21, 2007 | Merck |
| NCT00442936 | Phase 3 | Feb 15, 2007 | Merck |
| NCT00246337 | Phase 2 | Nov 1, 2005 | Merck |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 14 | 14 | 3 | 2005 |
1 organizations
Page 1 / 1